RESUMO

O mieloma múltiplo é uma neoplasia maligna caracterizada pela proliferação clonal de plasmócitos na medula óssea. O objetivo deste trabalho foi avaliar as possíveis associações entre o estado nutricional, força muscular e capacidade funcional de pacientes ambulatoriais portadores de mieloma múltiplo. Trata-se de estudo transversal realizado em amostra não probabilística de pacientes com mieloma múltiplo atendidos no Hospital das Clínicas, em Goiânia. Os dados foram coletados entre agosto e dezembro de 2015, utilizando-se de entrevistas e informações dos prontuários. O estado nutricional foi avaliado aplicando-se a Avaliação Subjetiva Global Produzida pelo Próprio Paciente; a força muscular medida por meio da Força do Aperto de Mão e a capacidade funcional, pela Escala de Performance de Karnofsky. O estudo foi aprovado pelo Comitê de Ética e Pesquisa do referido hospital. Foram avaliados 52 pacientes, em que 48,1% estavam desnutridos, 30,8% apresentavam baixa força muscular e 73,1%, comprometimento da capacidade funcional. A força muscular e a capacidade funcional foram menores nos desnutridos. Observou-se que aqueles que utilizavam corticoides apresentaram 18% menos chance de se tornarem desnutridos (OR=0,18; IC=0,05-0,62; p=0,011) porém, é importante considerar as possíveis causas de viés; por outro lado, os pacientes com baixa força muscular ou faziam quimioterapia apresentaram, aproximadamente, quatro vezes mais chances de desnutrição, respectivamente (OR=3,46; IC=0,99-12,08; p=0,047) (OR=3,64; IC=1,13-11,69; p=0,027). Concluiu-se que a desnutrição é comum nos pacientes portadores de mieloma múltiplo, indicando a necessidade premente de intervenção nutricional apropriada e precoce.

Multiple myeloma is a malignant neoplasm characterized by the clonal proliferation of plasma cells in the bone marrow. The objective of this study was to evaluate possible associations between nutritional status, muscle strength and functional capacity of outpatients with multiple myeloma. This is a cross-sectional study carried out on a non-probabilistic sample of patients with multiple myeloma treated at Hospital das Clínicas, in Goiânia. Data were collected between August and December 2015, using interviews and information from medical records. Nutritional status was assessed using the Patient Generated Subjective Global Assessment; muscular strength measured using Hand Grip Strength and functional capacity, using the Karnofsky Performance Scale. The study was approved by the Ethics and Research Committee of that hospital. 52 patients were evaluated, of which 48.1% were malnourished, 30.8% had low muscle strength and 73.1% had impaired functional capacity. Muscle strength and functional capacity were lower in malnourished individuals. It was observed that those who used corticosteroids were 18% less likely to become malnourished (OR=0.18; CI=0.05-0.62; p=0.011), however, it is important to consider the possible causes of bias; on the other hand, patients with low muscle strength or undergoing chemotherapy were approximately four times more likely to be malnourished, respectively (OR=3.46; CI=0.99-12.08; p=0.047) (OR=3.64; CI=1.13-11.69; p=0.027). It was concluded that malnutrition is common in patients with multiple myeloma, indicating the pressing need for appropriate and early nutritional intervention.

RESUMO

Introducción: El linfoma de Hodgkin es una enfermedad en la que se forman células malignas en el sistema linfático y que en los últimos años ha venido aumentando su presencia en la población. Objetivo: Caracterizar epidemiológicamente los linfomas de Hodgkin atendidos en el hospital de SOLCA - Guayaquil durante el periodo 2010-2021. Materiales y métodos: Se realizó un estudio de datos abiertos de diseño observacional, descriptivo, de corte transversal, de casos nuevos atendidos con linfoma de Hodgkin diagnosticados en el hospital de SOLCA Guayaquil, entre 2010 y 2021. Resultados: Las atenciones del linfoma de Hodgkin en el hospital de SOLCA Guayaquil fueron del 4 % en el 2010 y del 12 % en el 2021. Se tuvo sobre todo el linfoma de Hodgkin con esclerosis nodular, en hombres; los grupos etarios más frecuentes fueron hombres entre 0 y 19 años (37,7 %) y mujeres entre 20 y 29 años (45,3 %), procedentes de la provincia del Guayas. Conclusiones: Durante este periodo incrementaron las atenciones por linfoma de Hodgkin, en las que se observó más la esclerosis nodular en los pacientes, en hombres de 0 a 19 años y en mujeres de 20 a 39 años, similar al estándar de comportamiento de esta enfermedad

Introduction: Hodgkin lymphoma is a disease in which malignant cells form in the lymphatic system; its presence in the population has been increasing in recent years. Objective: Epidemiological characterization of the Hodgkin lymphomas treated at the SOLCA - Guayaquil hospital during the period 2010­2021. Material and methods: A study was carried out with open data from a cross-sectional observational descriptive design of the new cases of Hodgkin Lymphoma diagnosed and treated at the SOLCA - Guayaquil hospital between 2010 and 2021. Results: Hodgkin lymphoma care at the SOLCA - Guayaquil Hospital went from 4% in 2010 to 12% in 2021. Hodgkin lymphoma with nodular sclerosis was mostly observed in men; however, by age group, it was more frequent in men between 0 and 19 years old (37.7%) and in women between 20 and 29 years old (45.3%) from the Guayas province. Conclusions: During this period, Hodgkin lymphoma has garnered more attention due to an increase in nodular sclerosis cases observed in men aged 0 to 19 and women aged 20 to 39, which aligns with the standard behavior of this disease

Assuntos

RESUMO

Introducción: La infiltración del sistema nervioso central por células malignas constituye una complicación grave de algunas neoplasias hematológicas, principalmente leucemias agudas y linfomas agresivos. Objetivo: Resumir la base científica y la significación clínica de los métodos de estudio del líquido cefalorraquídeo para el diagnóstico y el seguimiento de la infiltración neuromeníngea en pacientes con neoplasias hematológicas. Métodos: Se buscó información durante abril de 2021 en las bases de datos PubMed, ScienceDirect y SciELO. Se seleccionaron las publicaciones en base a su tipología, actualidad, alcance y las limitaciones de los estudios. Conclusiones: El estudio citomorfológico del líquido cefalorraquídeo se considera el método estándar para el diagnóstico y el seguimiento de la infiltración neuromeníngea. La citometría de flujo resulta más sensible para la detección de infiltración oculta que la citología convencional; pero aún existen reservas sobre su significación clínica. Se investiga también la sensibilidad de otros estudios moleculares como el uso de la reacción en cadena de la polimerasa y la detección de biomarcadores(AU)

Introduction: Infiltration of the central nervous system by malignant cells constitutes a serious complication of some hematological malignancies, mainly acute leukemias and aggressive lymphomas. Objective: To summarize the scientific basis and clinical significance of cerebrospinal fluid study methods for the diagnosis and follow-up of neuromeningeal infiltration in patients with hematologic malignancies. Methods: Information was searched during April 2021 in PubMed, ScienceDirect and SciELO databases. Publications were selected based on their typology, timeliness, scope, and study limitations. Conclusions: The cytomorphological study of cerebrospinal fluid is considered the standard method for the diagnosis and follow-up of neuromeningeal infiltration. Flow cytometry is more sensitive for the detection of occult infiltration than conventional cytology, but there are still reservations about its clinical significance. The sensitivity of other molecular studies such as the use of PCR and biomarker detection is also investigated(AU)

Assuntos

RESUMO

INTRODUCCIÓN: Las infecciones fúngicas invasoras (IFI) en pacientes con neoplasias hematológicas (NH) representan un desafío diagnóstico y terapéutico. OBJETIVOS: Describir la etiología, características clínicas, diagnóstico y evolución de los episodios de IFI probadas y probables en pacientes con NH y trasplante de progenitores hematopoyéticos (TPH). PACIENTES Y MÉTODOS: Estudio descriptivo, retrospectivo y de cohorte que incluyó IFI probadas y probables en pacientes adultos con NH y TPH. Se realizó seguimiento hasta el día 90. RESULTADOS: Se incluyeron 80 episodios de IFI: 49% probadas y 51% probables, 67,5% por hongos filamentosos (HF), 30% por hongos levaduriformes (HL) y 2,5% por hongos dimorfos. Los tipos de IFI más frecuentes fueron aspergilosis invasoras pulmonares (AP) y candidiasis invasoras (CI), en su mayoría por Candida spp. no albicans. Todos los casos de AP se diagnosticaron por detección de galactomanano en sangre y/o lavado broncoalveolar, y solamente 22,2% presentaban nódulos con halo en la tomografía computada (TC) de tórax, siendo los infiltrados inespecíficos los hallazgos más frecuentes. Tuvieron coinfección bacteriana y viral el 30 y 17,5%, respectivamente. El 50% fueron IFI de brecha, y la mortalidad global y mortalidad relacionada a la IFI fue 51 y 24%, respectivamente. CONCLUSIÓN: Los HF fueron la principal causa de IFI, con una gran proporción de IFI de brecha, y presentaron elevada mortalidad. Para el diagnóstico, resulta importante la utilización de biomarcadores y jerarquizar cualquier imagen patológica en la TC.

BACKGROUND: Invasive fungal infections (IFI) in patients with hematological malignancies (HM) represent a diagnostic and therapeutic challenge. AIM: To describe the etiology, clinical characteristics, diagnosis and evolution of proven and probable IFI episodes in patients with HM and hematopoietic stem cell transplantation (HSCT). METHODS: Retrospective, descriptive, cohort study performed in adult patients with HM and HSCT, who developed proven and probable IFI. Follow-up was carried out until day 90. RESULTS: A total of 80 IFI episodes were included: 49% proven and 51% probable, 67,5% due to mold (M), 30% to yeast-like fungi (Y) and 2,5% to dimorphic fungi. The most frequent causes were probable pulmonary aspergillosis (PA) and invasive candidiasis (IC), mainly due to non-albicans Candida species. PA were all diagnosed by detection of galactomannan (GM) in blood and bronchoalveolar lavage, and only 22,2% presented halo sign on chest CT. Bacterial and viral coinfections were reported in 30% and 17,5% respectively. Breakthrough IFI occurred in 50%, and global and IFI-related mortality were 51% and 24% respectively. CONCLUSION: Mold was the main cause of IFI, with a large proportion of breakthrough IFI, presenting high mortality. The use of biomarkers and the classification of any pathological image on CT contribute to the diagnosis.

Assuntos

RESUMO

Abstract When a SARS-CoV-2 RT-qPCR test is performed, it may determine an indirect measureof viral load called cycle threshold (Ct). Respiratory samples with Ct <25.0 cycles are consideredto contain a high viral load. We aimed to determine whether SARS-CoV-2 Ct at diagnosis couldpredict mortality in patients with hematologic malignancies (lymphomas, leukemias, multiplemyeloma) who contracted COVID-19. We included 35 adults with COVID-19 confirmed by RT-qPCR performed at diagnosis. We evaluated mortality due to COVID-19 rather than mortalitydue to the hematologic neoplasm or all-cause mortality. Twenty-seven (27) patients survivedand 8 died. The global mean Ct was 22.8 cycles with a median of 21.7. Among the survivors,the mean Ct was 24.2, and the median Ct value was 22.9 cycles. In the deceased patients, themean Ct was 18.0 and the median Ct value was 17.0 cycles. Using the Wilcoxon Rank Sum test,we found a significant difference (p = 0.035). SARS-CoV-2 Ct measured in nasal swabs obtainedat diagnosis from patients with hematologic malignancies may be used to predict mortality.

Resumen Cuando se realiza una RT-qPCR para SARS-CoV-2, es posible determinar una medidaindirecta de la carga viral llamada umbral de ciclado (Ct). Las muestras respiratorias con Ct<25,0 ciclos se consideran de alta carga viral. Nos propusimos determinar si el Ct para SARS-CoV-2 al diagnóstico predice la mortalidad en pacientes con neoplasias hematológicas (linfomas,leucemias, mielomas) que contrajeron COVID-19. Incluimos 35 adultos con COVID-19 confirmadopor RT-qPCR al diagnóstico. Evaluamos la mortalidad por COVID-19, no la mortalidad por la neo-plasia hematológica o la mortalidad por cualquier causa. De los 35 pacientes, 27 sobrevivierony 8 fallecieron. El Ct global medio fue 22,8 ciclos con una mediana de 21,7 ciclos. Entre lossobrevivientes, el Ct medio fue 24,2 ciclos con una mediana de 22,9 ciclos. Entre los fallecidos,el Ct medio fue 18,0 y el Ct mediano fue 17,0 ciclos. Empleando la prueba de suma de rangosde Wilcoxon, encontramos una diferencia significative (p = 0,035). En pacientes con neoplasiashematológicas infectados con coronavirus, el Ct de SARS-CoV-2 medido en hisopados nasales almomento del diagnóstico podría ser utilizado para predecir la mortalidad.

RESUMO

Los pacientes con malignidades hematológicas tienen un riesgo más alto de hospitalización, admisión a cuidado crítico y muerte cuando contraen COVID-19. En este grupo se ha propuesto la vacunación y los refuerzos para disminuir el riesgo de complicaciones. Sin embargo, es posible ver una pobre respuesta humoral y celular a las vacunas. En esta revisión se presenta la evidencia sobre la respuesta a la vacunación, poniendo de presente algunas patologías y tratamientos que pueden disminuirla de forma significativa. Los pacientes con neoplasias hematológicas se deben considerar en riesgo de complicaciones, incluso después de haber sido vacunados de forma completa y haber recibido los refuerzos. Se debe mantener la vigilancia de forma estrecha después de haber sido vacunados y evaluar la posibilidad de otras estrategias (medicamentos, anticuerpos monoclonales) para la prevención o el manejo de COVID-19.

Patients with hematological malignancies have a higher risk of hospital admission, critical care and death when they suffer from COVID-19. In this group of patients, vaccination and boosters have been proposed to mitigate the risk of complications. However, it is possible to observe a diminished rate of humoral and cellular response. In this review, evidence is shown about the response to COVID-19 vaccination, considering some specific pathologies and treatments that can affect such response in a significant account. Patients with malignant neoplasm must be considered at risk of COVID-19 complications, even after a complete vaccine schedule and boosters. Surveillance must be maintained after vaccination over these patients and other strategies must be considered (drugs, monoclonal antibodies) for prevention and management of COVID-19.

Assuntos

RESUMO

When a SARS-CoV-2 RT-qPCR test is performed, it may determine an indirect measure of viral load called cycle threshold (Ct). Respiratory samples with Ct <25.0 cycles are considered to contain a high viral load. We aimed to determine whether SARS-CoV-2 Ct at diagnosis could predict mortality in patients with hematologic malignancies (lymphomas, leukemias, multiple myeloma) who contracted COVID-19. We included 35 adults with COVID-19 confirmed by RT-qPCR performed at diagnosis. We evaluated mortality due to COVID-19 rather than mortality due to the hematologic neoplasm or all-cause mortality. Twenty-seven (27) patients survived and 8 died. The global mean Ct was 22.8 cycles with a median of 21.7. Among the survivors, the mean Ct was 24.2, and the median Ct value was 22.9 cycles. In the deceased patients, the mean Ct was 18.0 and the median Ct value was 17.0 cycles. Using the Wilcoxon Rank Sum test, we found a significant difference (p=0.035). SARS-CoV-2 Ct measured in nasal swabs obtained at diagnosis from patients with hematologic malignancies may be used to predict mortality.

Assuntos

RESUMO

ABSTRACT Objectives: to identify the elements for assistance to patients with hematological malignancies to propose a care line. Methods: this is a scoping review, anchored in the JBI theoretical framework, with searches carried out in April 2021, in eight electronic databases and 10 repositories of theses and dissertations. Results: the final sample consisted of 93 studies, and the main forms of assistance provided that can support a care line for this public were imaging tests, immunophenotyping, chemotherapy regimens, radiotherapy, infection management, assessment of nutritional status, maintenance of oral function, symptom management and screening for second malignancies. Conclusions: the elaboration of a care line for onco-hematologic patients is necessary, considering the complexity surrounding the diagnosis and treatment of hematologic malignancies, in addition to the difficulties that are imposed in relation to access and continuity of care in the network.

RESUMEN Objetivos: identificar los elementos para la asistencia a pacientes con neoplasias hematológicas para proponer una línea de atención. Métodos: se trata de una revisión de alcance, anclada en el marco teórico del JBI, con búsquedas realizadas en abril de 2021 en ocho bases de datos electrónicas y 10 repositorios de tesis y disertaciones. Resultados: la muestra final estuvo compuesta por 93 estudios, y las principales formas de asistencia brindadas que pueden sustentar una línea de atención a este público fueron pruebas de imagen, inmunofenotipificación, regímenes de quimioterapia, radioterapia, manejo de infecciones, evaluación del estado nutricional, mantenimiento de la función oral, manejo de síntomas y detección de segundas neoplasias malignas. Conclusiones: es necesario el desarrollo de una línea de atención al paciente oncohematológico, dada la complejidad que rodea al diagnóstico y tratamiento de las neoplasias hematológicas, además de las dificultades que se imponen en relación al acceso y continuidad de la atención en una red.

RESUMO Objetivos: identificar os elementos para assistência a pacientes com neoplasias hematológicas para propor uma linha de cuidado. Métodos: trata-se de uma scoping review, ancorada no referencial teórico do JBI, com buscas realizadas em abril de 2021 em oito bases de dados eletrônicas e 10 repositórios de teses e dissertações. Resultados: a amostra final foi composta por 93 estudos, e as principais formas de assistências prestadas que podem embasar uma linha de cuidado para esse público foram exames de imagem, imunofenotipagem, regimes quimioterápicos, radioterapia, gestão de infecções, avaliação do estado nutricional, manutenção da função oral, gerenciamento de sintomas e rastreio para segundas neoplasias. Conclusões: a elaboração de uma linha de cuidados para pacientes onco-hematológicos se faz necessária, tendo em vista a complexidade que cerca o diagnóstico e tratamento das neoplasias hematológicas, além das dificuldades que se impõem em relação ao acesso e continuidade do cuidado em rede.

RESUMO

Introducción: Los jóvenes con enfermedades oncológicas enfrentan dificultades durante los períodos de diagnóstico, tratamiento y recuperación. Estos procesos complejos cargados de experiencias vitales inusitadas producen la transformación de su conciencia y los lleva a construir nuevos significados en la manera de comprender, relacionarse y actuar en el mundo que los rodea. Objetivo: Comprender el (re)significado de la vida a partir de la experiencia de los jóvenes que sobrevivieron al cáncer hematológico. Métodos: Estudio cualitativo, que utilizó la Teoría Fundamentada en Datos como metodología y el referencial de la Teoría de la Complejidad de Morin. Se realizaron entrevistas en profundidad a 12 adolescentes sobrevivientes de cáncer hematológico. El tamaño de muestra fue determinado al alcanzar nivel de saturación. El análisis fue simultáneo durante la recolección de los datos, mediante codificación abierta, axial y selectiva según lo señalan Strauss y Corbin. Resultados: Emergieron dos categorías: Reorganizando su vida por medio de cambios y aprendizajes para vencer al cáncer y, Asumiendo una mejor comprensión y compromiso con los demás y consigo mismo. Conclusiones: Las experiencias vividas por jóvenes sobrevivientes que padecen de cáncer modifican su forma de vivir y se tornan más comprensivos con el sufrimiento que ocasiona la enfermedad. Esta situación los hace más solidarios y comprometidos con su contexto social sobre todo con su familia y con pacientes oncológicos(AU)

Introduction: Young people with oncological diseases face difficulties during the periods of diagnosis, treatment and recovery. These complex processes loaded with unusual life experiences produce the transformation of their consciousness and lead them to construct new meanings in the way that they understand, relate and act in the world around them. Objective: To understand the (re)signification of life from the experience of young survivors of hematological cancer. Methods: A qualitative study was carried out, using the data driven theory as the methodology and Morin's complexity theory as the referent. In-depth interviews were conducted with twelve adolescent hematologic cancer survivors. The sample size was determined by reaching the saturation level. The analysis was simultaneous during data collection, using open, axial and selective coding according to Strauss and Corbin. Results: Two categories emerged: 1. reorganizing their life through changes and learning to overcome cancer and 2. assuming a better understanding and commitment to others and to themselves. Conclusions: The experiences lived by young cancer survivors modify their way of living as they become more understanding of the suffering caused by the disease. This situation makes them more supportive and committed to their social context, especially with their family and with cancer patients(AU)

Assuntos

RESUMO

O transplante de células-tronco hematoiéticas (TCTH) pode causar efeitos adversos no meio ambiente bucal, podendo influenciar a resposta do paciente ao tratamento e, consequentemente, no prognóstico. Este estudo objetivou identificar as alterações bucais mais prevalentes durante o período de internação para a realização do TCTH, analisar o tempo de desenvolvimento destas alterações neste mesmo período, bem como os fatores inerentes ao paciente e ao TCTH associados ao desenvolvimento destas alterações. Tratou-se de um estudo observacional, longitudinal, do tipo coorte, realizado em 30 pacientes assistidos pelo setor de transplante de medula óssea em um hospital de referência no Rio Grande do entre dezembro de 2021 a junho de 2022. Os dados sobre o exame físico bucal, diagnóstico da desordem hematológica, o tipo de transplante, as comorbidades, os protocolos quimioterápicos e os fatores de risco individuais dos pacientes no período do TCTH obtidos foram submetidos a testes estatísticos para estimar o tempo de surgimento das alterações e associação de fatores de risco. A significância estatística adotada foi de 5%. Dos 30 pacientes selecionados, 56,7% eram do sexo masculino, mediana de 35 anos, no qual 93,3% desenvolveram alguma alteração bucal e 53,3% iniciaram o tratamento com algum fator de risco bucal. As desordens hematológicas mais frequentes foram as leucemias (mieloide e linfoide) e os mielomas múltiplos (23,3% cada). O FluBuMel foi o protocolo de condicionamento mais utilizado (46,7%). A alteração bucal mais frequente foi o edema de mucosa jugal (83,3%) seguida da mucosite oral (80%; grau 01 - 54,2%). O tempo de seguimento foi em média 23 dias e, foi verificado que no 5.º dia de internação a probabilidade do paciente estar livre de alterações bucais foi de 93,3%, com essa taxa diminuindo ao longo do tempo, atingindo 6,7% no 28.º dia. O protocolo Mel200 foi associado ao desenvolvimento mais precoce das alterações bucais (p=0,02), assim como o transplante do tipo autólogo (p=0,004). Nossos resultados sugerem que o tempo de surgimento das alterações bucais é influenciado pelo tipo de transplante e protocolo de condicionamento quimioterápico e, adicionalmente, reforçam que a presença de um cirurgiã-dentista na equipe influencia positivamente no controle da severidade das alterações bucais (AU).

Hematopoietic stem cell transplantation (HSCT) can cause adverse effects in the oral environment that can affect the patient's response to treatment and prognosis. Thereby, this study aimed to identify the most prevalent oral alterations during the period of hospitalization for the performance of HSCT, to analyze the development time of these alterations in this period, as well as the factors associated with the development of these alterations. It was an observational, longitudinal, cohort study, carried out on patients assisted by the bone marrow transplant sector in a main hospital in Rio Grande do Norte between December 2021 and June 2022. Data about oral physical examination, diagnosis of hematological disorder, type of transplant, comorbidities, chemotherapy protocols and oral risk factors of patients obtained during the HSCT period were submitted to statistics tests to estimate the time of oral changes' onset and association of risk factors. The statistical significance adopted was 5%. 57.7% of the 30 selected patients were male, with a median age of 35 years, where 93.3% developed some oral alteration and 53.3% started treatment with some individual risk factor. The most frequent neoplasms were leukemias (myeloid and lymphoid) and multiple myeloma (23.3% each). FluBuMel was the most commonly used conditioning protocol (46.7%). The most frequent oral alteration was buccal mucosa edema (83.3%) followed by oral mucositis (80%; grade 1­54.2%). The follow-up time was on average 23 days and it was found that on the 5th day of hospitalization, the probability of the patient being free of alterations was 93.3%, with this rate decreasing over time, reaching 6.7% on the 28th day. The Mel200 protocol is associated with earlier development of alterations (p=0.02), as well as autologous transplantation (p=0.004). The results suggest that the time of onset oral alterations is affected by the type of transplant and chemotherapy conditioning protocol and, additionally, reinforce that the alterations' severity are positively affected by the presence of a dentist in the team (AU).

Assuntos

RESUMO

RESUMEN El linfoma del tejido linfoide asociado a las mucosas es una variedad poco común y recientemente descubierta del linfoma no Hodgkin. Suele presentarse en la sexta década de la vida, con un predominio del sexo femenino y en sitios como el tracto digestivo, pulmón, riñón, hígado, piel, y solo en el 2 % de los casos, en la glándula tiroides, donde en muchas ocasiones se asocia a la tiroiditis autoinmune de Hashimoto. Su evolución es favorable cuando se diagnostica en estadios iniciales de la enfermedad. Se presenta una paciente de 22 años, con una historia de trastornos endocrinos, perceptibles desde la adolescencia, a quien se le diagnosticó una tiroiditis de Hashimoto, sobre la que subyacía un linfoma del tejido linfoide asociado a las mucosas, y que evolucionó satisfactoriamente luego del tratamiento quirúrgico.

ABSTRACT Mucosa-associated lymphoid tissue lymphoma is a rare and recently discovered variant of non-Hodgkin's lymphoma. It usually occurs in the sixth decade of life, with a predominance of females and may be observed in sites such as the digestive tract, lung, kidney, liver, skin, and only in 2% of cases, in the thyroid gland, where in many occasions it is associated with Hashimoto's autoimmune thyroiditis. Its evolution is favorable when it is diagnosed in the initial stages of the disease. We present a 22-year-old female patient with a history of perceptible endocrine disorders since adolescence, who was diagnosed with Hashimoto's thyroiditis, underlying mucosa-associated lymphoid tissue lymphoma, and who evolved satisfactorily after surgical treatment.

Assuntos

RESUMO

BACKGROUND: Several studies to evaluate the accuracy of galactomannan (GM) in bronchoalveolar lavage fluid (BALF) as a diagnostic tool have been carried out; however, there are still controversies about the optimal cut-off point of BALF GM. AIMS: The objective of this study was to determine the diagnostic accuracy and the optimal cut-off point on BALF GM from patients with suspected invasive pulmonary aspergillosis (IPA) in a tertiary care hospital. METHODS: A cross-sectional study with 188 patients (≥18 years) that had undergone a bronchoscopy with BAL due to suspected IPA was carried out. IPA was diagnosed according to the EORTC/MSG guidelines. RESULTS: The optimal optical density cut-off point for BALF GM was 0.67, with sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 70%, 32.3%, and 100%, respectively. CONCLUSIONS: BALF GM detection proved to be a useful supplementary technique in the early diagnosis of IPA in both neutropenic and non-neutropenic patients.

Assuntos

RESUMO

INTRODUCCIÓN: La prevalencia de microorganismos multirresistentes es un problema de salud pública que continúa creciendo a lo largo del mundo. Existe una población principalmente susceptible de ser colonizada y posteriormente infectarse, son los pacientes oncológicos. OBJETIVO: Identificar las características clínicas y patológicas de los pacientes oncológicos y su relación con la infección con microorganismos productores de BLEE y EPC. PACIENTES Y MÉTODOS: Se condujo un estudio retrospectivo y de carácter analítico entre el primero de enero de 2019 y el 30 de junio de 2020 en tres unidades hemato-oncológicas. RESULTADOS: Incluyó a 3.315 pacientes, de los cuales 217 (6,5%) se encontraban colonizados por microorganismos productores de BLEE y EPC; de éstos, 106/217 (48,8%) presentaron al menos un episodio de infección. El microorganismo más frecuentemente aislado fue Klebsiella pneumoniae, en 29/106 (27,4%). De los infectados, 18/106 (17%) presentaron infección por el mismo microorganismo colonizador. La mucositis (p = 0,002), edad mayor a 65 años (p = 0,041), hipoalbuminemia (p < 0,01), neutropenia (p < 0,01) y la presencia dispositivos invasivos (p < 0,01) demostraron una relación con el desarrollo de infección. CONCLUSIÓN: La presencia de hipoalbuminemia (OR 3,3, IC 1,5-7,1, p < 0,01), dispositivos invasivos (OR 5,8, IC 3.0-11,4, p < 0,01) y neutropenia (OR 4,1, IC 1,5-11,4, p < 0,01) predicen el desarrollo de infecciones.

BACKGROUND: The prevalence of multi-resistant microorganisms is a public health problem that continues to grow globally. There is a population that is mainly susceptible to being colonized and subsequently infected, and these are cancer patients. AIM: To identify the clinical and pathological characteristics of cancer patients and their relationship with infection with ESBL and CPE producing microorganisms. METHODS: A retrospective and analytical study was conducted between January 1, 2019 and June 30, 2020 in three hematooncological units. RESULTS: We included 3315 patients of which 217 (6.5%) were colonized by microorganisms producing ESBL and CPE. Of these, 106/217 (48.8%) had at least one episode of infection. The most frequently isolated microorganism was Klebsiella pneumoniae 29/106 (27.4%). Of those infected, 18/106 (17%) presented infection by the same colonizing microorganism. Mucositis (p = 0.002), age over 65 years (p = 0.041), hypoalbuminemia (p < 0.01), neutropenia (p < 0.01) and the presence of invasive devices (p < 0.01) demonstrated a relationship with development of infection. The presence of hypoalbuminemia (OR 3.3, CI 1.5-7.1, P < 0.01), invasive devices (OR 5.8, CI 3.0-11.4, p < 0.01) and neutropenia (OR 4.1, CI 1.5-11.4, p < 0.01) predict the development of infections.

Assuntos

RESUMO

Este trabalho realizou um estudo retrospectivo dos prontuários do Hospital das Clínicas (HC) da Universidade Federal de Minas Gerais (UFMG). Foram incluídos os indivíduos admitidos no período de 2010 a 2021 com diagnóstico de leucemia/linfoma e que foram avaliados pela equipe do Serviço de Odontologia do HC­UFMG. Foram coletados dados demográficos, características clínicas da doença de base e da cavidade bucal e presença de infiltração oral maligna. O teste t não pareado foi utilizado para avaliar os hemogramas e o teste McNemar para comparar indivíduos que desenvolveram infiltração oral maligna e aqueles que não desenvolveram. A significância estatística foi estabelecida como p<0,05. Adicionalmente, uma revisão da literatura de relatos de casos e séries de casos foi realizada em quatro bases de dados eletrônicas (PubMed, Web of Science, Scopus e Embase). Dos 781 prontuários analisados, a leucemia linfocítica aguda (30,1%) foi o diagnóstico mais frequente. Pacientes nas duas primeiras décadas de vida foram mais acometidos pela doença de base. Cárie (36,7%) e alterações periodontais (34,6%) foram as condições bucais mais observadas. Infiltração oral maligna ocorreu em 25 (3,2%) indivíduos, envolvendo principalmente a gengiva (80%) e indivíduos diagnosticados com leucemia mieloide aguda (64%). Comparando os dados de pacientes pediátricos que desenvolveram infiltração maligna e aqueles que não desenvolveram, a proporção de óbitos foi maior naqueles que tiveram infiltração (p=0,002), enquanto em adultos, aqueles que desenvolveram infiltração exibiram pior condição periodontal e maior proporção de óbitos (p<0,001). Dados da revisão da literatura demonstraram que a infiltração oral maligna foi mais frequente na gengiva (37%) e em pacientes com leucemia mieloide aguda (47%). As principais características clínicas e de imagem associadas à infiltração oral foram aumento de volume e lesões osteolíticas. Em conjunto, os dados sugerem a importância do monitoramento clínico odontológico de pacientes com leucemia/linfoma considerando os piores desfechos clínicos relacionados à infiltração dos tecidos orais.

This work carried out a retrospective study of the medical records at the Hospital das Clínicas (HC), Universidade Federal de Minas Gerais (UFMG). Individuals admitted in the period from 2010 to 2021 with a diagnosis of leukaemia/lymphoma and who were evaluated by the team of the dental service of HC­UFMG were included. Demographic data, clinical characteristics of the underlying disease and oral cavity, and presence of malignant oral infiltration were collected. The unpaired t test was employed to assess the blood count and the McNemar test to compare individuals who developed malignant oral infiltration and those who did not. Statistical significance was set at p<0.05. Additionally, a literature review of case reports and case series was undertaken in four electronic databases (PubMed, Web of Science, Scopus, and Embase). Of the 781 medical records analysed, acute lymphocytic leukaemia (30.1%) was the most frequent diagnosis. Patients in the first two decades of life were more affected by the underlying disease. Caries (36.7%) and periodontal changes (34.6%) were the most frequently observed oral conditions. Oral malignant infiltration took place in 25 (3.2%) individuals, mainly involving the gingiva (80%) and individuals diagnosed with acute myeloid leukaemia (64%). Comparing data from paediatric patients who developed malignant infiltration and those who did not, the proportion of deaths was higher in those who had infiltration (p=0.002), while in adults, those who developed infiltration had worse periodontal status and a higher proportion of death (p<0.001). Data from the literature review showed that oral malignant infiltration was more frequent in the gingiva (37%) and in patients with acute myeloid leukaemia (47%). The main clinical and imaging features associated with oral infiltration were swelling and osteolytic lesions. Altogether, the data suggest the importance of clinical dental monitoring of patients with leukaemia/lymphoma considering the worst clinical outcomes related to oral tissue infiltration.

Assuntos

RESUMO

Com o objetivo de contribuir para a gestão do Sistema único de Saúde (SUS) no que se refere às neoplasias hematológicas (NH), este trabalho apresenta a elaboração de dois estudos: (a) analise de custos por hospitalização por NH, e (b) avaliação de custo-efetividade da adição de daratumumabe ao esquema de tratamento do Mieloma Múltiplo (MM) em pacientes não elegíveis para transplante autológico de células tronco hematopoiéticas (TCTH). Por meio da extração de dados do sistema de internações hospitalares do SUS, desenvolveu-se uma análise retrospectiva descritiva de frequências e custos das internações por NH de acordo com sua distribuição temporal, espacial (por estados e regiões), e por patologia, na década compreendida entre os anos de 2010 e 2019. Foram também calculados custo médio pro procedimento e taxa de acesso. Foi observado que houve uma tendência de crescimento estável das frequências e dos custos ao longo do período analisado. Além disso, contatou-se uma significativa discrepância na frequência dos procedimentos entre as regiões Norte e Sudeste, que registraram o menor e o maior número de procedimentos, respectivamente. Observou-se também eu a frequência das internações por patologia não refletiu a incidência estimada pela literatura no país para cada uma das patologias avaliadas. Para o estudo de custo-efetividade, foi desenvolvido um modelo de simulação de sobrevida particionado para a adição do daratumumabe ao esquema de tratamento composto por bortezomibe, melfalano e prednisona (VMP). O horizonte temporal de 30 anos e a perspectiva de análise do SUS, foram usados. Com base nos dados da literatura foi possível observar que a adição deste medicamento ao VMP no tratamento desses pacientes pode aumentar a sobrevida global e a sobrevida livre de progressão. Considerados os custos relacionados a esta tecnologia e ao manejo do paciente no cenário brasileiro, no entanto, a inclusão do daratumumabe está aparentemente acima do limiar de aceitabilidade adotado pelo SUS. Para que esta estratégia seja custo-efetiva no cenário observado, a tecnologia precisaria sofrer uma redução de quase 50% no custo. O estudo, portanto, não recomenda a adição do daratumumabe ao VMP no tratamento do MM em pacientes não elegíveis para TCTH.

Aiming to contribute to the management of the Brazilian Public Health System (SUS) regarding hematologic malignances (NH), this work presents the development of two studies: (a) cost analysis per hospitalization for NH, and (b) cost-effectiveness evaluation of adding daratumumab to the treatment scheme for Multiple Myeloma (MM) in patients not eligible for autologous hematopoietic stem cell transplantation (TCTH). By extracting data from the SUS hospital admissions system, we developed a retrospective descriptive analysis of frequencies and costs of NH admissions according to their temporal, spatial distribution (by states and regions), and by pathology, in the decade between the years 2010 and 2019. Average cost per procedure and access rate were also estimated. It was observed that there was a stable growth trend in frequencies and costs over the analyzed period. Furthermore, a significant discrepancy in the procedure frequency was found between the North and Southeast regions, which recorded the lowest and highest number of procedures, respectively. It was also observed that the frequency of hospitalizations per pathology did not reflect the incidence estimated by the literature in the country for each of the pathologies evaluated. For the cost-effectiveness study, a partitioned survival simulation model was developed for the inclusion of daratumumab in the treatment scheme consisting of bortezomib, melphalan, and prednisone (VMP). A 30-year time horizon and the perspective of the SUS were used for the analysis. Based on literature data, it was possible to observe that the inclusion of this drug to VMP in the treatment of these patients can increase overall survival and progression-free survival. Considering the costs related to this technology and patient management in the Brazilian scenario, however, the inclusion of daratumumab is seemingly above the threshold of acceptability adopted by SUS. For this strategy to be cost-effective in the observed scenario, the technology would require a cost reduction of almost 50%. The study, therefore, does not recommend the inclusion of daratumumab to VMP in the treatment of MM in patients not eligible for TCTH.

Assuntos

RESUMO

Resumo Objetivos: identificar fatores de risco ocupacionais para neoplasias hematológicas, leucemia, linfomas e mieloma múltiplo. Métodos: estudo caso-controle conduzido com casos de neoplasias hematológicas e controles recrutados do mesmo serviço, com outros diagnósticos, pareados por frequência, sexo e idade. Entrevistas individuais foram realizadas por pesquisadores treinados, utilizando um questionário estruturado. Informações sobre a história ocupacional, uso e características de exposições a substâncias químicas, em geral, e a agrotóxicos foram registradas. Foram estimadas odds ratios (OR), por meio de modelos de regressão logística não-condicional multivariável para análise exploratória. Resultados: foram incluídos 61 casos e 146 controles. Trabalho na agropecuária (OR: 2,18; intervalo de confiança de 95% (IC95%): 1,10;4,30), exposição ocupacional a agrotóxicos (OR: 2,37; IC95%: 1,18;4,77), e tempo total de exposição ocupacional a agrotóxicos na vida laboral em horas - curto (OR: 3,52; IC95%: 1,25;9,87) e longo (OR: 3,95; IC95%: 1,54;10,14) - foram fatores de risco para neoplasias hematológicas, em comparação aos não expostos. Essas medidas foram ajustadas por consumo de álcool e tabagismo, prática de atividade física, renda, escolaridade e história de exposição ocupacional a produtos químicos. Conclusão: a exposição ocupacional a agrotóxicos se associa a neoplasias hematológicas, independentemente de características do estilo de vida e nível socioeconômico.

Abstract Objectives: to identify the occupational risk factors for hematological neoplasms, specifically leukemia, lymphomas, and multiple myeloma. Methods: this is a case-control study. Cases were individuals with hematological neoplasms and controls were individuals with other diagnoses; frequency-matched by sex and age. Individual interviews were conducted by trained researchers using a structured questionnaire. We collected information on participants' occupational history and chemicals use and exposure, in general, and pesticides, in particular. Odds ratios (OR) were used as association measurements, estimated by multivariate non-conditional logistic regression models for exploratory analysis. Results: 61 cases and 146 controls were included. We found that agricultural work (OR: 2.18; 95% confidence interval (95%CI): 1.10;4.30), occupational exposure to pesticides (OR: 2.37; 95%CI: 1.18;4.77), and total occupational exposure to pesticides throughout their working life (in hours) - both short (OR: 3.52; 95%CI: 1.25;9.87) and long (OR: 3.95; 95%CI: 1.54;10.14) - constituted risk factors for hematological neoplasms, when compared to those unexposed. We adjusted these measures for alcohol consumption and smoking, physical activity, income, education, and history of occupational exposure to chemicals. Conclusion: occupational exposure to pesticides is associated with hematological neoplasms regardless of lifestyle and socioeconomic status.

Assuntos

RESUMO

As neoplasias mieloproliferativas crônicas (NMPC) são doenças hematopoiéticas clonais que acometem a linhagem mieloide. De acordo com a Organização Mundial de Saúde (OMS), a policitemia vera (PV), a trombocitemia essencial (TE) e a mielofibrose (MF) são classificadas como NMPC BCR-ABL negativas. O surgimento dessas doenças está correlacionado com fatores genéticos, como mutações nos genes JAK2, MPL e CALR e outras mutações cooperantes que também podem estar presentes, levando ao aparecimento de diferentes fenótipos e prognósticos. A OMS constantemente revisa e atualiza os critérios de classificação, levando em consideração aspectos clínicos, morfológicos e genéticos. As análises laboratoriais, hematológicas e genéticas são de grande importância para o diagnóstico das neoplasias hematológicas, e devem ser realizadas da forma correta para permitir o diagnóstico diferencial entre outras neoplasias e distúrbios reacionais. O presente trabalho tem como objetivo revisar a fisiopatologia das NMPC e relacionar com os achados clínicos, hematológicos e genéticos, visando instruir e atualizar os analistas clínicos para que possam efetivamente contribuir para o diagnóstico dessas doenças, impactando o prognóstico dos pacientes. Ainda, a discussão sobre diagnóstico molecular tem o intuito de chamar a atenção para a constante evolução da área e importância desta para a hematologia.

The Chronic Myeloproliferative Neoplasms (MPN) are hematopoietic disease that affect the myeloid lineage cells. According to WHO, the Polycythemia vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) are classified as BCR-ABL negative neoplasms. The occurrence of these diseases is correlated with genetics factors, as mutations in the JAK2, MPL e CALR genes and other cooperative mutations that may also be present, leading to different phenotypes manifestations and prognostics. WHO revises and updates constantly these diseases' classification criteria, considering clinical, morphological and genetic aspects. Laboratory tests, both hematological and genetic, have a key rule at these diseases' diagnosis and must be performed correctly in order to ensure a differential diagnosis from other neoplasms and reactive disorders. This manuscript aims to revise the MPN's physiopathology linking it to clinical, hematological and genetical findings, aiming to instruct and update clinical analysts so they can contribute to those diseases' diagnostic, impacting the patients' prognostics. Furthermore, the considerations about molecular diagnostics have the intention of emphasize the constant evolution of this subject and its importance to hematology.

RESUMO

RESUMO Objetivo: Determinar a incidência cumulativa de falência aguda de órgão e internamento em unidade de terapia intensiva em pacientes oncológicos. Métodos: Estudo de coorte prospectivo de pacientes oncológicos adultos em tratamento sistêmico antineoplásico, internados de forma não programada. Resultados: Entre agosto de 2018 e fevereiro de 2019, 10.392 pacientes foram submetidos a tratamento sistêmico antineoplásico, sendo que 358 necessitaram de internamento hospitalar não programado e foram elegíveis para inclusão; por fim, 258 desses pacientes foram incluídos. A média de idade foi de 60,9 anos, e 50,9% eram do sexo masculino; 17,9% dos pacientes tinham câncer hematológico. O risco acumulado de falência de órgãos foi de 39,6% (IC95% 35 - 44) e o risco de internamento na unidade de terapia intensiva em pacientes com falência aguda de órgão foi de 15,0% (IC95% 12 - 18). À admissão em internamento, 62,1% dos pacientes foram considerados não elegíveis para terapia de substituição artificial de órgãos. O tempo mediano de seguimento foi de 9,5 meses. A mortalidade hospitalar foi de 17,5%, na unidade de terapia intensiva de 58,8%. A mediana de sobrevivência da coorte foi de 134 dias (IC95% 106 - 162). Na análise multivariada, a falência aguda de órgão se associou com a mortalidade aos 6 meses após a alta (hazard ratio: 1,6; IC95% 1,2 - 2,2). Conclusão: O risco de falência aguda de órgão em pacientes oncológicos admitidos para tratamento hospitalar não programado durante o tratamento sistémico foi de 39,6% e o risco de internamento em unidade de terapia intensiva foi de 15,0%. A falência aguda de órgão em pacientes oncológicos foi um fator de prognóstico independente para maior mortalidade intra-hospitalar e menor sobrevivência aos 6 meses após a alta.

ABSTRACT Objective: To ascertain the cumulative incidence of acute organ failure and intensive care unit admission in cancer patients. Methods: This was a single-center prospective cohort study of adult cancer patients admitted for unscheduled inpatient care while on systemic cancer treatment. Results: Between August 2018 and February 2019, 10,392 patients were on systemic treatment, 358 had unscheduled inpatient care and were eligible for inclusion, and 285 were included. The mean age was 60.9 years, 50.9% were male, and 17.9% of patients had hematologic cancers. The cumulative risk of acute organ failure was 39.6% (95%CI: 35 - 44), and that of intensive care unit admission among patients with acute organ failure was 15.0% (95%CI: 12 - 18). On admission, 62.1% of patients were considered not eligible for artificial organ replacement therapy. The median follow-up time was 9.5 months. Inpatient mortality was 17.5%, with an intensive care unit mortality rate of 58.8% and a median cohort survival of 134 days (95%CI: 106 - 162). In multivariate analysis, acute organ failure was associated with 6-month postdischarge mortality (HR 1.6; 95%CI: 1.2 - 2.2). Conclusion: The risk of acute organ failure in cancer patients admitted for unscheduled inpatient care while on systemic treatment was 39.6%, and the risk of intensive care unit admission was 15.0%. Acute organ failure in cancer patients was an independent poor prognostic factor for inpatient hospital mortality and 6-month survival.

Assuntos

RESUMO

Resumen La infección por SARS-CoV-2 en pacientes con neoplasias hematológicas y trasplantes de células progenitoras hematopoyéticas (TCPH) puede ser grave y con importante mortalidad. Llevamos a cabo un estudio prospectivo y observacional que tuvo como objetivo describir las características clínicas, epide miológicas y la evolución de la infección por SARS-CoV-2 en pacientes con neoplasias hematológicas y TCPH. Se incluyeron 20 pacientes adultos con una mediana de edad de 58 años y una mediana de score de Charlson de 3. Las infecciones fueron de adquisición comunitaria y nosocomial en el 60% y 40% respectivamente, y el 30% de los pacientes tenía antecedente de contacto con una persona infectada por SARS-CoV-2. El 65% pre sentó infiltrados pulmonares, mayormente con patrón de vidrio esmerilado en la tomografía computarizada de tórax. Casi la mitad de los pacientes tuvo enfermedad grave y crítica, y una alta proporción recibió plasma de convalecientes como tratamiento. Presentaron complicaciones e infecciones hospitalarias el 20% y 15% respec tivamente, y tuvieron una mediana de días de internación prolongada. La mortalidad a 30 días fue del 10%. La infección por SARS-CoV-2 en nuestra población tuvo considerable impacto clínico y epidemiológico.

Abstract. SARS-CoV-2 infection in patients with hematological malignancies and hematopoietic stem cell transplants (HSCT) can be severe and with significant mortality. We carried out a prospective and observational study to describe the clinical and epidemiological characteristics and outcome of SARS-CoV-2 infection in patients with hematological malignancies and HSCT. Twenty adult patients were included with a median age of 58 years and a median Charlson score of 3. Infections were community-acquired and nosocomial in 60% and 40%, respectively, and 30% of the patients had a history of contact with a SARS-CoV-2 infected person. Sixty-five percent had pulmonary infiltrates, mostly with a ground-glass pattern on CT scan. Almost half of the patients had a severe and critical illness, and a high proportion received convalescent plasma as treatment. Twenty percent and 15% had complications and hospital infections, respectively, and had prolonged hospitalization expressed as median days of it. The 30-day mortality was 10%. SARS-CoV-2 infection in our population had a considerable clinical and epidemiological impact.

Assuntos

RESUMO

O Transplante de Medula Óssea (TMO) é um tratamento potencialmente curativo para doenças hematológicas e de alguns tumores sólidos. Os pacientes submetidos a TMO que são admitidos na UTI apresentam altas taxas de mortalidade nos curto e longo prazos. No entanto, devido a melhoras nos cuidados destes pacientes, os resultados têm sido progressivamente melhores. O presente estudo tem o objetivo de descrever a sobrevida global, hospitalar e em 1 ano dos pacientes submetidos à TMO e que foram internados na UTI, comparar a sobrevida em 1 ano de pacientes submetidos ao transplante autólogo e ao transplante alogênico. Nós realizamos um estudo de coorte retrospectiva, com os pacientes submetidos a TMO admitidos à UTI do A.C. Camargo Câncer Center, no período de setembro de 2009 a dezembro de 2018. Foram incluídos pacientes acima de 18 anos que internaram na UTI no prazo de até 1 ano após a realização do transplante de medula óssea. Caso o paciente apresentasse mais de uma passagem pela UTI, somente a primeira foi considerada para análise. Realizamos um modelo de regressão de Cox para avaliar o impacto do tipo de TMO na sobrevida de 1 ano, sem e com ajuste para a idade do paciente. Durante o período de estudo, foram realizados 942 TMO. Houve 117 (12,4%) admissões à UTI de pacientes com menos de 1 ano do TMO. Um total 83 pacientes foram incluídos no estudo, sendo 57 (68,7%) submetidos a TMO autólogo e 26 (31.3%) a TMO alogênico. A mortalidade na UTI foi de 38,5% (n=10) no grupo de TMO alogênico e 12,3% (n=7) de TMO autólogo (p<0,01). Mortalidade hospitalar também foi maior para o grupo alogênico (n=15, 57,7%) versus (n=12, 21,1%) no autólogo (p<0,01). A mediana de sobrevida dos pacientes após a admissão na UTI foi de 400 (IC 95% 133 ­ 1476) dias. Mediana de sobrevida após a admissão na UTI foi de 50,5 (IC 95%, 20 ­ 430) dias para receptores de TMOalogênico e 1115 (IC 95%, 337 ­ NA) dias para receptores de TMO autólogo. O TMO alogênico foi associado a um aumento de mortalidade em um ano quando comparado com o TMO autólogo, tanto no modelo não ajustado [HR = 2.79 (IC=95%, 1.48-5.26)] quanto no modelo ajustado para a idade e score SOFA [HR ajustado = 2.62 (IC95%, 1.29-5.31)].

Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for many hematological malignancies and some solid tumors. HSCT recipients who require intensive care unit (ICU) admission have high mortality rates. However, due to improvements in the care of these patients, the results have been progressively better. The present study aims to describe the overall, hospital and 1-year survival of HSCT recipients who were admitted to the ICU, comparing the 1-year survival of autologous transplantation and allogeneic transplantation. We performed a retrospective cohort study with HSCT recipients patients admitted to the AC Camargo Cancer Center's ICU from September 2009 to December 2018. Patients 18 years and older who were admitted to the ICU within 1 year after the HSCT was included. If the patient had more than one visit to the ICU, only the first one was considered for analysis. We did a Cox regression model to assess the impact of HSCT type on 1-year survival, with and without adjustment for age. During the study period, there were 942 HSCT in our center. There were 117 (12.4%) admissions to the ICU. 83 patients were included in the study, 57 (68.7%) autologous HSCT and 26 (31.3%) allogeneic HSCT. Mortality in the ICU was 38.5% (n=10) for allogenic HSCT recipients and 12.3% (n=7) for autologous HSCT recipients (p<0.01). Hospital mortality was also higher for allogeneic HSCT recipients (n=15, 57.7%) compared to (n=12, 21.1%) autologous HSCT recipients (p<0.01). The median survival of patients after admission to the ICU was of 400 (95% CI 133 ­ 1476) days. Median survival after admission to the ICU was of 50.5 (95% CI, 20 ­ 430) days for allogeneic HSCT recipients and 1115 (95% CI, 337 ­ NA) days for autologous HSCT recipients. Allogeneic HSCT was associated with increased mortality at one year when compared to autologous HSCT, both in the unadjusted model [HR = 2.79 (CI=95%, 1.48-5.26)] and in the age and SOFA scoreadjusted model [HR-adjusted = 2.62 (95%CI, 1.29-5.31)].

Assuntos